Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 11.06.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
11.06.23Intellia Therapeutics, Inc.: Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)325Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients (n=10), a single dose of NTLA-2002 led to a...
► Artikel lesen
11.06.23Kura Oncology, Inc.: Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress274- 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) - - 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations...
► Artikel lesen
11.06.23Ocular Therapeutix, Inc.: Ocular Therapeutix Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD493OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic...
► Artikel lesen